Th17 helper cell and T-cell immunoglobulin and mucin domain 3 involvement in Guillain-Barré syndrome

ISSN： 0892-3973

Source： Immunopharmacology and Immunotoxicology, Vol.34, Iss.6, 2012-12, pp. : 1039-1046

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vaccines and Guillain-Barré Syndrome

By Haber Penina

Drug Safety, Vol. 32, Iss. 4, 2009-01 ,pp. : 309-323

Adis International

Access to resources Recommend Favorite

Guillain-Barré syndrome

By Pritchard Jane

Clinical Medicine, Vol. 10, Iss. 4, 2010-08 ,pp. : 399-401

Royal College Of Physicians

Access to resources Recommend Favorite

Can IFN- be used in Guillain-Barré syndrome?

Inpharma, Vol. 1, Iss. 1252, 2000-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Guillain-Barré Syndrome: Epidemiology, Pathophysiology and Management

By Kuwabara S.

Drugs, Vol. 64, Iss. 6, 2004-01 ,pp. : 597-610

Adis International

Access to resources Recommend Favorite

Major Surgery with Guillain–Barré Syndrome: a Case Report

By Koc M Ozalp N Zulfikaroglu B

The Journal of International Medical Research, Vol. 30, Iss. 6, 2002-11 ,pp. : 601-604

Field House Publishing

Access to resources Recommend Favorite